4 hours MYGN Beats on Q3 Earnings and Revenues, Raises ’24 EPS ViewZacks
Myriad Genetics delivers strong third-quarter results, driven by growth within Pharmacogenomics and Prenatal. The company increases its full-year EPS guidance.
XMyriad Genetics delivers strong third-quarter results, driven by growth within Pharmacogenomics and Prenatal. The company increases its full-year EPS guidance.
X